Company / Named in our posts
Kineta.
Follow KinetaA clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies that address cancer immune resistance.[1]
01Deal
Deals on Carrywatch
Every deal that names Kineta, and its role in each.
Janssen Pharmaceutica NV / Kineta
Janssen Pharmaceutica NV buys Kineta, Inc. product rights
See deal detailsDeal Web
Kineta and 0 firms it shares a posted deal with, and the path to any other firm.
Financials
5 fiscal years of figures as Kineta reported them.
News
Loading headlines.
Sources
As of 24 Oct 2026.
- 01Kineta, Inc. Form 8-K
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
- 02Kineta Completes Reverse Merger with Yumanity Therapeutics
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
Deal posts naming Kineta:
- P01